Navigation Links
Simcere's Branded Generic Formulation Biqi Passes EU-GMP Inspection
Date:8/23/2011

NANJING, China, Aug. 23, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that Biqi, a branded generic anti-diarrhea drug, has passed EU-GMP inspection.

The EU-GMP certificate was issued following a four-day EU-GMP audit conducted in April 2011. The inspection covered product formulation, manufacturing process, facilities and quality management systems. On August 16, 2011, the inspectors from the Fimea officially announced that Biqi meets the criteria of EU-GMP requirements for production and quality control, and issued the EU-GMP certificate to the Company.

In 2010, Simcere's manufacturing facility for diosmectite, the API in Biqi, successfully passed EU-GMP inspection.

Mr. Ren Jinsheng, Chairman of the Board of Simcere, said: "As a leading pharmaceutical company, it is our mission to provide excellent drugs for patients. We are pleased that Biqi has passed a high-standard quality control certification. This is a major milestone for Simcere."

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics. The Company has introduced an innovative anti-cancer medication Endu, first-to-market generics such as Bicun and Anxin, and a first-to-market medication Sinofuan. Simcere manufactures and sells drugs in the oncological, cardiovascular, anti-inflammatory and anti-infection therapeutical areas. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence or mortality rates and for which there is a clear demand for more effective pharmacotherapy including cancer and cardiovascular, cerebrovascular, inflammatory and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:

Yehong Zhang

President

Simcere Pharmaceutical GroupTel: 86-25-8556-6666 ext 8811In the United States:

Kate Tellier

Brunswick Group

Tel: 1-212-333-3810In Beijing:

Yue Yu

Brunswick Group

Tel: 86-10-5960-8600In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: 852-3512-5000  
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Par Pharmaceutical Companies Announces a Restructuring of Its Branded Division, Strativa Pharmaceuticals, to Maximize Profitability
2. Branded Pharmaceutical Websites Continue to Be Most Impactful in Driving Conversions Among Prospects and Patients
3. GNC Teams With Sakar International for Branded Health and Wellness Product Line
4. Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies
5. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
6. International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line
7. Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
8. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
9. Lupin Expands Branded Play
10. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
11. Prasco® Launches Authorized Generic with Shionogi Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... ... for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 ... , Dr. Maisel, founder of Retina Group of New York , is ...
(Date:5/26/2016)... ... , ... Memorial Day Weekend marks the unofficial start of summer and the ... make sure your family and vehicle are ready to hit the road this weekend. ... deaths and an additional 50,500 serious injuries from motor vehicle crashes during the three-day ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The ... to host a six-week smoking cessation class starting June 6 at their clinic in ... http://www.gnahec.org . , Additionally, the Lung Institute has created a free downloadable 4 ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic ... medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an ... during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a ... first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led by ... through the 8 hour interactive course to qualify participants as certified PowerWave trainers. ...
Breaking Medicine News(10 mins):